A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

Launched by CSTONE PHARMACEUTICALS · Dec 10, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Nofazinlimab (CS1003) for patients with advanced liver cancer, specifically a type called hepatocellular carcinoma (HCC) that cannot be surgically removed. The trial aims to find out how well Nofazinlimab works when given alongside another medication called lenvatinib, compared to lenvatinib with a placebo (a non-active treatment). Participants must be at least 18 years old, have a confirmed diagnosis of HCC that is not eligible for surgery or local treatments, and have not received any previous systemic treatments for their cancer.

If you join this trial, you will receive either the new treatment or a placebo along with lenvatinib, and your progress will be closely monitored. The study is currently active but not recruiting new participants. It is important to note that certain health conditions and previous treatments may exclude individuals from participating, so a thorough review of your medical history will be conducted. Additionally, if you are a woman of childbearing age, you will need to have a negative pregnancy test and use birth control during the trial. This trial could help researchers understand better ways to treat advanced liver cancer and improve patient outcomes.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • 1. Age ≥18 years on the day of signing informed consent-(For Taiwan, the lower limit of age is 20 years).
• • 2. Subjects with unresectable advanced HCC, that is not eligible for surgery and/or locoregional therapy (Stage B or C based on Barcelona Clinic Liver Cancer \[BCLC\] staging system, and meets either one of the following criteria: 1) histologically or cytologically confirmed diagnosis of HCC, 2) clinically confirmed diagnosis of HCC according to American Association for the Study of Liver Diseases (AASLD) criteria. Patients without cirrhosis require histological confirmation of diagnosis.
• • 3. With at least one measurable lesion can be assessed
• • 4. Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
• • 5. Life expectancy ≥ 3 months.
• • 6. Child-Pugh A
• • 7. No prior systemic treatment for advanced HCC
• • 8. Subjects with hepatitis B virus (HBV) infection, are willing to continue receiving antiviral treatment while on study.
• • 9. Subjects have adequate organ and marrow function. Female subjects with childbearing potential must have negative serum pregnancy test result at screening. Female subjects with childbearing potential, and male subjects and their female partners with childbearing potential must agree to use an contraceptive method(s) from the day of signing informed consent form (ICF), during the study and till at least 6 months after the last dose of study treatment.
• • Exclusion criteria
• • 10. Fibrolamellar-HCC, sarcomatoid, cholangiocellular carcinoma or mixed cholangiocarcinoma and HCC.
• • 11. A prior bleeding event due to esophageal within 6 months or other gastrointestinal bleeding events within 28 days prior to screening.
• • 12. Malabsorption syndrome or inability to take oral medication due to other causes.
• • 13. HBV and HCV co-infection.
• • 14. Investigator evaluates to increase the drug related risk caused by enrolling subjects in trial and taking study drug, or any serious or uncontrolled systematic disease that confound the drug absorption or the study outcome, e,g diabetes mellitus, hypertension, rheumatoid arthritis, major cardiovascular disease and so on.
• • 15. Surgery or locoregional therapy for palliative purpose within 4 weeks prior to study treatment.
• • 16. History of other malignancy(ies) in the past 5 years, except for malignant disease treated with curative intent and without active disease.
• • 17. Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
• • 18. Current or prior use of systemic corticosteroid (\> 10 mg/day prednisone or equivalent) or other immunosuppressive medication within 14 days prior to the first dose of study treatment.
• • 19. History of bone marrow transplantation or organ transplantation.
• • 20. History of anaphylaxis or hypersensitivity to any ingredient of the investigational product.
• • 21. Any contraindication of lenvatinib.
• • 22. Known history of drugs abuse that would interfere with cooperation with the requirements of the trial.
• • 23. Pregnant or lactating female subjects.
• • 24. History of psychiatric disease that would interfere with cooperation with the requirements of the trial; lack of or with restricted physical capability.
• • 25. QTc interval \> 470 msec (as calculated with Fridericia's formula) at screening electrocardiogram (ECG);
• • 26. Any condition that would in the investigator's judgment, prevent the subject from participating in this study.